LOQTORZI Revenue Jumps 61% in Q1, Coherus Oncology Advances Key Pipeline Programs
CHRS has more than doubled off its 52-week low of $0.71 on elevated volume (2.6× avg).
Summary
Coherus Oncology reported strong first-quarter 2026 financial results, with LOQTORZI net revenue reaching $11.8 million, marking a 61% increase year-over-year. The company also ended the quarter with a solid cash position of $167.0 million. This positive financial update follows the company's strategic pivot to focus exclusively on oncology, as outlined in its recent 10-K filing. Furthermore, Coherus provided encouraging business updates on its pipeline, confirming patient accrual completion for the 1L HCC Phase 2 trial for casdozokitug and continued development for tagmokitug, with multiple data readouts expected throughout 2026. Traders will be watching for these upcoming data readouts, particularly for casdozokitug around mid-year and tagmokitug in mid-2026 and 2H 2026, as well as the anticipated initiation of the pasritamig combination study in the fall.
At the time of this announcement, CHRS was trading at $1.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $300.7M. The 52-week trading range was $0.71 to $2.62. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.